Please join ITIF for an expert panel discussion examining where Japan faltered in this sector, what it must do to restore its life-sciences innovation leadership and competitiveness, why that would be in the best interests of both Japan and the United States—and what America must do to avoid following in Japan’s footsteps.

Watch the release event of a new report that examines the dynamics that underpin the economics of biopharmaceutical innovation and how to maintain a supportive environment that keeps the United States in the lead of life-sciences innovation.

ITIF hosted a panel discussion with leading experts on innovation policy, technology transfer, and business, who spoke to the practical implications of exercising federal “march-in” rights and why it would be a grave and ill-timed mistake for the U.S. health, competitiveness, and research landscape.

ITIF hosted an expert panel discussion about the report and the vital role IP has played throughout the pandemic.

ITIF hosted an expert panel discussion exploring the groundbreaking innovations and policy considerations impacting the field of multi-cancer early detection.

Investments in biopharmaceutical innovation and expenditures on medicines themselves both produce tremendous societal returns. Maintaining the robust innovation ecosystem necessary to capitalize on these benefits requires the right mix of “push” and “pull” incentives.

Peer-reviewed research finds that pharmaceutical innovation provides direct and indirect benefits for health-care use and disability.

The bill fails to recognize three critical realities: 1) that drug prices are, in fact, not a significant driver of raging inflation; 2) that there exist better mechanisms to reform Medicare Part D drug pricing practices; 3) that mandated government price controls do inflict serious harm on nations’ life-sciences innovation systems.

Congress should ignore pressure from progressive activists who want to use drug price controls to move to a government-led drug discovery and production system and instead focus on more pragmatic reforms.

The WTO’s approval of a TRIPS waiver for IP related to COVID-19 vaccines is essentially a shotgun blast completely missing the broadside of a barn.

The United States uniquely leads the world in innovating new drugs and getting them to patients first while sustaining a globally competitive industry and over time making drugs affordable by incentivizing competition and creating generic pathways.

ITIF’s Center for Life Sciences Innovation advocates for accelerating biopharmaceutical innovation by recognizing that the public and private sectors both have essential roles to play in advancing the technology, economic, and policy factors that underpin it.